Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.80 |
| ▸ | APP | P05067 | 1/20 | 0.66 |
| ▸ | BCHE | P06276 | 8/20 | 0.53 |
| ▸ | CNR2 | P34972 | 5/20 | 0.53 |
| ▸ | ACHE | P22303 | 5/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 6/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5408050 | 1.00 | SLC2A1 (0.80) | SLC2A1APPBCHECNR2ACHE | |
| SCHEMBL14580350 | 0.95 | SLC2A1 (0.73) | SLC2A1APPBCHECNR2ACHE | |
| SCHEMBL14580330 | 0.95 | SLC2A1 (0.73) | SLC2A1APPBCHECNR2ACHE | |
| SCHEMBL908232 | 0.93 | SLC2A1 (0.80) | SLC2A1APPBCHECNR2ACHE | |
| SCHEMBL5421779 | 0.93 | SLC2A1 (0.80) | SLC2A1APPBCHECNR2ACHE | |
| SCHEMBL30403756 | 0.93 | SLC2A1 (0.80) | SLC2A1APPBCHECNR2ACHE | |
| SCHEMBL11671890 | 0.92 | SLC2A1 (0.78) | SLC2A1APPBCHECNR2ACHE | |
| SCHEMBL14580337 | 0.91 | SLC2A1 (0.77) | SLC2A1APPBCHECNR2ACHE | |
| SCHEMBL14580354 | 0.91 | SLC2A1 (0.77) | SLC2A1APPBCHECNR2ACHE | |
| SCHEMBL14580357 | 0.90 | SLC2A1 (0.75) | SLC2A1APPBCHECNR2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7173061-B2 | Compounds for imaging alzheimer's disease | GE HEALTHCARE LIMITED (GB) | 2007-02-06 | — | — | US | disclosed |
| US-7173061-B2 | Compounds for imaging alzheimer's disease | GE HEALTHCARE LIMITED (GB) | 2007-02-06 | — | — | US | disclosed |
| US-7173061-B2 | Compounds for imaging alzheimer's disease | GE HEALTHCARE LIMITED (GB) | 2007-02-06 | — | — | US | disclosed |
| US-20050080130-A1 | Compounds foriImaging alzheimer's disease | GE HEALTHCARE LIMITED (GB) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080130-A1 | Compounds foriImaging alzheimer's disease | PSEN1, APP, PSEN2 | SLC2A1 901/4885APP 2/4885BCHE 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.